Sarepta Therapeutics (SRPT) vs Zenas BioPharma (ZBIO)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 8, 2026.
Summary
Zenas BioPharma (ZBIO) has outperformed Sarepta Therapeutics (SRPT) over the past year, gaining 35.2% versus a loss of 24.3%. Sarepta Therapeutics is the larger company by market cap ($1.89 billion vs $1.70 billion), about 1.1 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | SRPT | ZBIO |
|---|---|---|
| Share price | $17.92 | $26.13 |
| Market cap | $1.89B | $1.70B |
| 1-day change | +2.40% | -7.27% |
| YTD return | -18.68% | -22.39% |
| 1-year return | -24.31% | +35.16% |
| 5-year return | -79.21% | — |
| Forward P/E | 7.43 | — |
| EPS (TTM) | $-1.57 | $-9.63 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $24.68 | $44.60 |
| 52-week low | $14.68 | $13.50 |
| Distance from 52-week high | -27.39% | -41.41% |
| Analyst consensus | hold | strong_buy |
| Avg. price target upside | +21.26% | +83.24% |
| Average volume | 2.98M | 735.12K |
| Shares outstanding | 105.63M | 65.18M |
| Employees | 835 | 167 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- ZBIO has outperformed SRPT by 59.5 percentage points over the past year.
About Sarepta Therapeutics
SRPT stock →Sarepta Therapeutics, Inc., a commercial-stage biopharmaceutical company, focuses on the discovery and development of RNA-targeted therapeutics, siRNA platform, gene therapy, and other genetic therapeutic modalities for the treatment of rare diseases. It offers EXONDYS 51 for the treatment of Duchenne in patients who have a confirmed mutation of the dystrophin gene that is amenable to exon 51 skipping; VYONDYS 53 for the treatment of Duchenne in patients who have a confirmed mutation of the dystrophin gene that is amenable to exon 53 skipping; AMONDYS 45 for the treatment of Duchenne in patients who have a confirmed mutation of the dystrophin gene that is amenable to exon 45 skipping; and ELEVIDYS, an AAV-based gene therapy, which is contraindicated in patients with any deletion in exon 8 and/or exon 9 in the Duchenne gene.
Health Care · Biotechnology: Pharmaceutical Preparations · 835 employees
About Zenas BioPharma
ZBIO stock →Zenas BioPharma, Inc., a clinical-stage biopharma company, engages in the development and commercialization of transformative immunology-based therapies. Its lead product candidate is obexelimab, a bifunctional monoclonal antibody designed to bind CD19 and Fc?RIIb for the treatment of various I&I diseases and various indications, including immunoglobulin G4-related disease, multiple sclerosis, and systemic lupus erythematosus.
Health Care · Biotechnology: Pharmaceutical Preparations · 167 employees
SRPT vs ZBIO FAQ
Which is bigger, Sarepta Therapeutics or Zenas BioPharma?
Sarepta Therapeutics (SRPT) is larger, with a market capitalization of $1.89B compared with $1.70B for Zenas BioPharma (ZBIO).
Which stock has performed better over the past year, SRPT or ZBIO?
ZBIO returned +35.16% over the past 12 months, compared with -24.31% for SRPT (price return, excluding dividends). Past performance does not predict future results.
Are Sarepta Therapeutics and Zenas BioPharma in the same industry?
Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.